

November 8, 1985

United States Nuclear Regulatory Commission Region III Materials Licensing Section 799 Roosevelt Road Glen Ellyn, Illinois 60137

Dear Sirs:

You will find enclosed three(3) proposed amendments to our NRC license number 21-05432-04. Enclosed you will find a check in the amount of \$120.00 for the required licensing fee.

If you should have any questions concerning these amendments please feel free to contact me.

Sincerely,

Ray Wery

Physicist

Marquette General Hospital Marquette, Michigan 49855

1-906-225 3102

U.S. K.R.C.

RECEIVED

RFW/ra

No

Che...

Туро

Received By

8601210103 BE

CONTROL NO. 80153

3601210103 851231 REG3 LIC30 21-05432-04 PDR RECEIVED

NOV 18 1985

REGION III

NOV 1 8 1985

A. Radioactive materials storage area roof of the St. Lukes Building

Please amend our NRC License #21-05432-04 to indicate that we use an area on teh roof of teh St. Lukes Building for storage of radioactive material waste. This area is used to store short half-life radioactive waste material generated in the Nuclear Medicine Department until it has decayed to background levels.

- You will find enclosed a diagram of the storage area. The storage area is a room with concrete walls and ceiling with a metal door which is locked at all times. The door is posted to indicate the presence of radioactive material.
- Movement of materials to the storage is done by or under the supervision of Nuclear Medicine department personnel.
- A radiation survey was done on 25-Oct-85.
 Below you will find a summary of that survey.

Direction		Loca	tio	<u>n</u>	Exposure	rate
North	outer	wall	of	storage	<0.1	mR/hr
		area				
South	outer	wall	of	storage	< 0.1	mR/hr
		area				
East		Door			<0.1	mR/hr
Below	Em	ploye	e 1	ocker		mR/hr

Background = <0.1mR/hr
Keithley Model#36150 Survey meter
calibrated April, 1985

MARQUETTE GENERAL Hospital
RADIOACTIVE MATERIALS STORAGE
ROOF ST. Lukes Building

EDGE OF Building RAdioactivic 1'= 1/4" STORAGE AREA METAL Locked Door posted with codiation WALLING SIGN Building WANKWAY Adjacent To Buildine STORACE Limited Access
Special Key
NEEDED Roof Locked AREA door EDEE of Building

AREA BELOW RADIOCTURE Storage Area
- Employee locker and storage Area
- G.M READING At background level

B. Addition of authorized users to License #21-05432-04

Please amend this NRC License to include the following authorized users:

Peter A. Lassing, M.D. Teofilo L. Sia, M.D. Ethelbert M. Lara, M.D.

Attached you will find documentation as to their training and experience.

NRC FORM 313M SUPPLEMENT A

U.S. NUCLEAR REGULATORY COMMISSION

(9-81)

TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

Teofilo L. Sia, M. D.

2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE Michigan

	3. CERTIFICATION	
SPECIALTY BOARD	CATEGORY	MONTH AND YEAR CERTIFIED
American College of Diagnostic Radiology	Radiology	6/81

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

		TYPE AND LENGT	H OF TRAINING
FIELD OF TRAINING	LOCATION AND DATE (S) OF TRAINING	LECTURE/ LABORATORY COURSES (Hours)	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	Bronx-Lebanon Hospital Center Bronx, NY	120	35
b. RADIATION PROTECTION	Same as above	40	0
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	" " "	40	0
d. RADIATION BIOLOGY	п п п	50	0
e. RADIOPHARMACEUTICAL CHEMISTRY	" " "	65	0

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUN	The End Children Who Ghite	DURATION OF EXPERIENCE	TYPE OF USE
Tc ⁹⁹ m	10 Ci	Marquette General Hospital 420 W. College Avenue Marquette, MI 49855	July 1, 1983 to present	Diagnostic Radiology
Mo99	28.6 Ci	same as above	Same as above	
I 131	10 mCi	и и и	11 11 11	11
T1 201	55 mCi	11 11 11	11 11 11	"
Ga ⁶⁷	80 mCi			"
Xe 133	700 mCi	" " "	11 11 11	"
In 111	5 mCi	11 11 11	11 11 11	"

PRECEPTOR STATEMENT

plement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

APPLICANT PHYSICIAN'S NA	ME AND ADDRE	SS	KEY TO COLUMN C
FULL NAME Teofilo L. Sia, M.	D.		PERSONAL PARTICIPATION SHOULD CONSIST OF: 1. Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
STREET ADORESS 1414 W. Fair Avenu	10		2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
CITY	I STATE MI	1 ZIP CODE 49855	3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	(Additional information or comments may be submitted in duplicate on separate sheets.)
	DIAGNOSIS OF THYROID FUNCTION	12	
	DE TERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
1-131	LIVER FUNCTION STUDIES		
or 1-125	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	11	
	IN VITRO STUDIES		
OTHER			
1-125	DETECTION OF THROMBOSIS		
1-131	THYROID IMAGING	12	
P-32	EYE TUMOR LOCALIZATION		
Se- 75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER	In 111 Cisternography	5	
	BRAIN IMAGING	10	
	CARDIAC IMAGING	2	
	THYROID IMAGING	30	
	SALIVARY GLAND IMAGING	2	
Tc-99m	BLOOD POOL IMAGING	16	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	96	
	LUNGIMAGING	49	
	BONE IMAGING	128	
OTHER	Gastrointestinal	4	

PRECEPTOR STATEMENT (Continued) 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued) NUMBER OF CASES INVOLVING COMMENTS ISOTOPE CONDITIONS DIAGNOSED OR TREATED PERSONAL (Additional information or comments may be PARTICIPATION submitted in duplicate on separate sheets,) D P.32 TREATMENT OF POLYCYTHEMIA VERA. (Soluble) LEUKEMIA, AND BONE METASTASES P-32 INTRACAVITARY TREATMENT (Colloidal) TREATMENT OF THYROID CARCINOMA 1-131 TREATMENT OF HYPERTHYROIDISM Au-198 INTRACAVITARY TREATMENT Co-60 INTERSTITIAL TREATMENT Cs-137 INTRACAVITARY TREATMENT 1-125 INTERSTITIAL TREATMENT or 1r-192 Co-60 TELETHERAPY TREATMENT Cs-137 Sr-90 TREATMENT OF EYE DISEASE RADIOPHARMACEUTICAL PREPARATION Mo-99/ GENERATOR 5 Elutions Sn-113/ GENERATOR In-113m Tc-99m REAGENT KITS 5 Kit preps Other 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING July 1, 1983 to present - average 36 patients a month 4. THE TRAINING AND EXPERIENCE INDICATED ABOVE 6. PRECEPTOR'S SIGNATURE WAS OBTAINED UNDER THE SUPERVISION OF: a. NAME OF SUPERVISOR

21-05432-04 NRC FORM 313M SUPPLEMENT B (9-81)

Marquette, MI 49855
5. MATERIALS LICENSE NUMBERISI

b. NAME OF INSTITUTION

c. MAILING ADDRESS

John F. Pillote, M. D.

420 W. College Avenue

Marquette General Hospital

8. DATE

7. PRECEPTOR'S NAME (Please type or print)

John F. Pil'ote, M. D.



THE BRONX-LEDANON HOSPITAL CENTER

AFFILIATED WITH ALBERT EINSTEIN COLLEGE OF MEDICINE

FULTON AVENUE AT 169TH STREET BRONX, N.Y. 10456 (212) 588-7000 CONCOURSE DIVISION 1650 GRAND CONCOURSE

BRONX, NEW YORK 10457

FULTON DIVISION 1276 FULTON AVENUE BRONX, NEW YORK 10456

THE BRONX-MORRISANIA AMBULATORY CARE UNIT 1309 FULTON AVENUE BRONX, NEW YORK 10456

August 28, 1985

To Whom It May Concern:

Dr. Teofilo Sia was a Resident in our Department from 1972 to 1976. During these four years, he was in attendance on our program's weekly didactic lectures on the Physics of Nuclear Medicine and Radiation Biology. These were given by Mr. Joseph Warmund, who is a Board Certified Physicist, as well as other Professors from Albert Einstein College of Medicine who periodically came as guest lecturers. Dr. Sia was assigned to six months in the Department of Nuclear Medicine where he became very proficient and commendably knowledgeable in this Specialty.

This letter is not just to confirm that he had attended the program faithfully, but also to commend him highly.

Yours Truly,

Prospero Sanidad, M.D. Radiologist-In-Charge Concourse Division

PS/sg

NRC FORM 313M SUPPLEMENT A

U.S. NUCLEAR REGULATORY COMMISSION

(9-81)

TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

Peter A. Lassing, M. D.

2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE Michigan

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED	
erican Board of Radiology	Diagnostic Radiology	6/77	

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

		TYPE AND LENGT	TYPE AND LENGTH OF TRAINING	
FIELD OF TRAINING	LOCATION AND DATE (S) OF TRAINING	LECTURE/ LABORATORY COURSES (Hours)	SUPERVISED LABORATORY EXPERIENCE (Hours) D	
a. RADIATION PHYSICS AND INSTRUMENTATION	National Naval Medical Center Bethesda, Maryland Course #7602 (Jan Mar. 1976	63	17	
b. RADIATION PROTECTION	Same as above	18	0	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	" " "	28	0	
d. RADIATION BIOLOGY	" " "	9	0	
e. RADIOPHARMACEUTICAL CHEMISTRY	" " "	30	0	

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOU	WHERE EXPERIENCE WAS GAINED	DURATION OF THE TRIENCE	TYPE OF USE
Tc 99m Ga 67 T1 201	50 Ci 600 mCi 120 mCi	Marquette General Hospital 420 W. College Avenue Marquette, MI 49855 same as above	July 9, 1979 to present same as above	Diagnostic Radiology
Xe 133	7 C1	и и п	" " "	
		" " "		
I 131	1 Ci		" " "	"
In 111	5 mCi	" " "	11 11 11	"
Yb 111	5 mCi	11 11 11	" " "	

NRC FORM 313M Supplement A

(9-81)

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAMI	E AND ADDRE	ss
FULL NAME	Trans.	
Peter A. Lassing, M.	. D.	
1414 W. Fair Avenue		
CITY	STATE	ZIP CODE
Marquette	MI	49855

KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF:

- 1 Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment,

	PARTITION OF PARTITION OF THE PARTITION	NUMBER OF	
ISOTOPE	CONDITIONS DIAGNOSED OR TREATED B	CASES INVOLVING PERSONAL PARTICIPATION C	(Additional information or comments may be submitted in duplicate on separate sheets.)
	DIAGNOSIS OF THYROID FUNCTION	48	Combination of clinical experie ce
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		at Bethesda Medical Center (Jan. 76 to Mar. 76), and Marquette General
1-131	LIVER FUNCTION STUDIES		Hospital, Marquette, MI (July, 79
1-125	FAT ABSORPTION STUDIES		to present)
	KIDNEY FUNCTION STUDIES	75	
	IN VITRO STUDIES	1,669	
OTHER		1 1 1 1 1 1 1 1	
1-125	DETECTION OF THROMBOSIS		
1-131	THYROID IMAGING	110	
P-32	EYE TUMOR LOCALIZATION		
Se- 75	PANCREAS IMAGING	1	
Yb-169	CISTERNOGRAPHY	13	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER	I 131 Thyroid chest survey	3	
	BRAIN IMAGING	268	
	CARDIAC IMAGING		
	THYROID IMAGING	209	
	SALIVARY GLAND IMAGING	10	
Tc-99m	BLOOD POOL IMAGING	45	
	PLACENTA LOCALIZATION	5	
	LIVER AND SPLEEN IMAGING	590	
	LUNG IMAGING	237	
	BONE IMAGING	716	
OTHER			

PRECEPTOR STATEMENT (Continued) 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued) NUMBER OF CASES INVOLVING COMMENTS PERSONAL ISOTOPE (Additional information or comments may be CONDITIONS DIAGNOSED OR TREATED submitted in duplicate on separate sheets,) PARTICIPATION C D P-32 TREATMENT OF POLYCYTHEMIA VERA. (Soluble) LEUKEMIA, AND BONE METASTASES P-32 INTRACAVITARY TREATMENT (Colloidal) TREATMENT OF THYROID CARCINOMA 1-131 TREATMENT OF HYPERTHYROIDISM Au-198 INTRACAVITARY TREATMENT Co-60 INTERSTITIAL TREATMENT or Cs-137 INTRACAVITARY TREATMENT 1-125 INTERSTITIAL TREATMENT or Ir-192 Co-60 TELETHERAPY TREATMENT Cs-137 Sr-90 TREATMENT OF EYE DISEASE RADIOPHARMACEUTICAL PREPARATION Mo-99/ Tc-99m GENERATOR 5 Elutions Sn-113/ GENERATOR In-113m Tc-99m REAGENT KITS 5 Kit preps Other 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING July 9, 1979 to present - average 36 patients a month 4. THE TRAINING AND EXPERIENCE INDICATED ABOVE 6. PRECEPTOR'S SIGNATURE WAS OBTAINED UNDER THE SUPERVISION OF: a. NAME OF SUPERVISOR John F. Pillote, M. D. b. NAME OF INSTITUTION 7. PRECEPTOR'S NAME (Please type or print) Marquette General Hospital c. MAILING ADDRESS 420 W. College Avenue John F. Pillote, M. D. d. CITY 8. DATE Marquette, MI 49855 5. MATERIALS LICENSE NUMBER(S) 21-05432-04

NRC FORM 313M SUPPLEMENT B (9-81)

The state of the s

NATIONAL NAVAL MEDICAL CENTER

BETHESDA, MARYLAND - 20014

NNMC:C95:JAT:jt 1520 10 July 1978

LT Peter A. Lassing, MC, USNR Radiology Department Naval Regional Medical Center Oakland, California 94627

Dear Dr. Lassing:

The following information is enclosed for your records and for use when applying for a NRC By Products Materials License.

Part 4 to Form NRC-313M-Supplement A (7-77) 10 CFR 30

	4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING		TYPE AND LENGTH OF TRAINING		
	FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING	LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours)	
	a. RADIATION PHYSICS AND INSTRUMENTATION	National Naval/Medical Center Bethesda, Maryland Course #7602 (19 Jan 76 to	63 (80 total hr	17 (s)	
A.	b. RADIATION PROTECTION	05 Mar 76) Same as block a	18	0	
100	c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	Same as block a	28	0	
	d. RADIATION BIOLOGY	Same as block a	9	0	
	e. RADIOPHARMACEUTICAL CHEMISTRY	Same as block a	30	0	

The training and experience indicated above was obtained under the supervision of:

Richard F. Kiepfer, CDR, MC, USN Head, Nuclear Medicine Branch



WHITE STATES ALOMIC THERE IT COMMISSION

APPLICATION FOR BYPRODUCT ME IERIAL LICENSE-MEDICAL

SUPPLEMENT A -- PRECEPTOR STATEMENT

This page is to be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each. Back of page may be used for comments

P. NAME AND ADDRESS OF APPLICANT PHYSICIAN (Include ZIP Code.)

Peter A. Lassing LT MC USNR

10. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN NAMED IN ITEM 9 ABOVE IAI (C) (D) ISCIOPE CONDITIONS DIAGNOSED OR TREATED No. Cases Involving Personal No. Coses Observed (See 1 in key below) Participation (See 2 in key below) 1-131 Diagrasis of thyroid function 48 13 Dilution studies Excretion studies Brain tumor localization Scanning studies Thyroid Chest Survey Treatment of hyperthyroidism Treatment of cardiac conditions Treatment of thyroid earcinoma Treatment of polycythemia P-32 Soluble Treatment of Irukemia Irrestment of bone metastases Tumor localization Introcavitary treatment Interstitudi breutment Au-153 Introduce volume to retrievent Interstition trealment Scuring studies Cr - 51 Alpert determinations Southern studies Co 59 0. Diagraphs of permitious anemia Ca - 60 Co-00 Interstation treater at 1-1-2 faliachydary treatment Co-6" 01 Teleti-ropy heatment Cs-13/ 51. 90 To absent of superficirly discuses of the age Other Tc-99m Brain Scan 268 268 'sotopies Tc-99m Brain Flow 268 Use back 268 Tc-99m Liver Scan of page 104 104

off and (0) above

TO THE SAME HOLD NOW POR SECRET . S. SOME AS KAUGISCHOPE PRABING. 19 JAN - 05 MAR 1976

Certified to be a true copy

J. Morton LCDR MSC USN

billy THE SUFERVISION OF C. W. OCHS, CAPT, MC, USN Chairman, Dept. of Radiology NNMC, Bethesda, Md. 20014

NNMC, BETHESDA, MD. These courses stop or and Asi Lond

19-02891-05

I'm a short then real forecase (4) moves).

Leadure of Precaptory

I is his original should consist at obeset up autocoping a humistichian to forequest and discussion with presents the case of its establish most appropriate diagnostic and on therego are remodern, locational, resemblications,

I have not productive of the reset of later research come channel potents to divine, a see most only the up. to have any seasoned to be decided get as grown laten an distance to be promoted, they beds make mentioned has been need the military admission of the sound to the potents. wholes out if the every remains of the colored more noments and pleating of costs, and set of measure property of framing to every the physician to money's summer are permits upon in tell or patients through I up as and or the course of us award

. UNITED STATES ATOMIC ENERGY ! MAISSION

APPLICATION FOR BYPRODUCT MATERIAL LICENSE-MEDICAL SUPPLEMENT A-HUMAN USE

PAGE 4

This page may be used to	providing additional information.		
		. "C"	"D"
Тс-99ш	Spleen Scan	104	104
Tc-99m		21	21
Tc-99m		21	21
Tc-99m		21	21
Tc-99m		3	3
Tc-99m		1	
Tc-99m	Parotid Scan	5	1 5 2
Tc-99m	Bone Marrow Scan	2	2
Tc-99m	Thyroid Scan	59	59
Tc-99m	Bone Scan	89	89
Tc-99m	Meckel's Scan	1	1
Ga-67	Whole Body Scan	30	30
Xe-133	Ventillation and Perfusion Study	8	8
1-125	T-3 Test	304	304
I-124	T-4 Test	1,314	1,314
1-131	Rose Bengal - Biliary Patency	1	1
Se-75	Pancreas Scan	1	1
In-111	Cisternography	3	3
Co-57	B-12 Assay	50	50
Co-57	Schillings Test	1	1

NRC FORM 313M SUPPLEMENT A

U.S. NUCLEAR REGULATORY COMMISSION

(9-81)

TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER

NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER

2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE Michigan

Ethelbert M. Lara, M. D.

SPECIALTY BOARD	CATEGORY MONTH AND YEAR CERT		
0-11			

American College of Diagnostic Radiology

Radiology

3. CERTIFICATION

12/76

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

		TYPE AND LENGTH OF TRAINING		
FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING	LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D	
a. RADIATION PHYSICS AND INSTRUMENTATION	Brooklyn-Cumberland Medical Center Brooklyn, NY	112	31	
b. RADIATION PROTECTION	Same as above	30	0	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	" "	50	0	
d. RADIATION BIOLOGY	" " "	50	0	
e. RADIOPHARMACEUTICAL CHEMISTRY	" " "	53	0	

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
Tc ⁹⁹ m	60 Ci	Marquette General Hospital 420 W. College Avenue Marquette, MI 49855	June 1, 1978 to	Diagnostic Radiology
Mo 99	171 C1	same as above	Same as above	11
I 131	60 mCi	11 11 11	11 11 11	"
T1 201	150 mCi	11 11 11	11 11 11	"
Ga 67	480 mCi	11 11 11		н
Xe 133	4.2 Ci	" " "	" " "	,
In 111	6.0 mCi	11 11 11	m m n	"

NRC FORM 313M Supplement A

(9-81)

CONTROL NO. 80153

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

APPLICANT PHYSICIA	N'S NAM	ME A	ND ADDRE	SS
FULL NAME				
Ethelbert M.	Lara,	М.	D.	
STREET ADDRESS				
1414 W. Fair	Avenue	•		
CITY		-	STATE	ZIP CODE
			MI	49855

KEY TO COLUMN C PERSONAL PARTICIPATION SHOULD CONSIST OF:

- Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
- 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
- 3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment,


2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	(Additional information or comments may be submitted in duplicate on separate sheets.)
	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	1837 July 1831 - 1	
1-131	LIVER FUNCTION STUDIES		
1-125	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES	70	
	IN VITRO STUDIES		
OTHER			
1-125	DETECTION OF THROMBOSIS	Market Hall	
1-131	THYROID IMAGING	72	
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY	10	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER	In 111 Cisternography	14	
	BRAIN IMAGING	90	
	CARDIAC IMAGING	5	
Tc-99m	THYROID IMAGING	150	
	SALIVARY GLAND IMAGING	10	
	BLOOD POOL IMAGING	50	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	486	
	LUNG IMAGING	208	
	BONE IMAGING	627	
OTHER	Gastrointestinal	21	

PRECEPTOR STATEMENT (Continued) 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued) NUMBER OF CASES INVOLVING COMMENTS CONDITIONS DIAGNOSED OR TREATED ISOTOPE PERSONAL (Additional information or comments may be PARTICIPATION submitted in duplicate on separate sheets,) A B C D P-32 TREATMENT OF POLYCYTHEMIA VERA, (Soluble) LEUKEMIA, AND BONE METASTASES P-32 INTRACAVITARY TREATMENT (Colloidal) TREATMENT OF THYROID CARCINOMA 1-131 TREATMENT OF HYPERTHYROIDISM Au-198 INTRACAVITARY TREATMENT Co-60 INTERSTITIAL TREATMENT Cs-137 INTRACAVITARY TREATMENT 1-125 INTERSTITIAL TREATMENT or Ir-192 Co-60 or Cs-137 TELETHERAPY TREATMENT Sr-90 TREATMENT OF EYE DISEASE RADIOPHARMACEUTICAL PREPARATION Mo-99/ Tc-99m GENERATOR 5 Elutions Sn-113/ GENERATOR In-113m Tc-99m 5 Kit preps REAGENT KITS Other 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING June 1, 1978 to present - average 36 patients a month

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:	6. PRECEPTOR'S SIGNATURE
John F. Pillote, M. D.	Jo Hillest -
Marquette General Hospital	7. PRECEPTOR'S NAME (Please type or print)
420 W. College Avenue	John F. Pillote, M. D.
Marquette, MI 49855	8. DATE
5. MATERIALS LICENSE NUMBER(S) 21-05432-04	

NRC FORM 313M SUPPLEMENT B (9-81)





THE BROOKLYN HOSPITAL

23 August 1985

To whom it may concern:

Dr. Ethelbert Lara, completed his residency in radiology on the 30th of June 1976. Dr. Lara was at the Brooklyn Hospital from July 1, 1973 through June 30, 1976. At the time of his residency completion Dr. Lara was eligible for the American Board of Radiology. As part of his training, a rotation through Nuclear Medicine was done which included the Physics of Nuclear Medicine and Nuclear Biology. Following completion of his residency, Dr. Lara was with us as an Attending Radiologist in Vascular Radiology from July 12, 1976 through July 31, 1976.

I trust the above information will be of help in evaluating Dr. Lara's present position.

Yours truly,


Anthony Camera, M.D.

C. An alternative method of verification of Dose Calibrator linearity

Please amend our NRC License #21-05432-04 to include the following alternative procedure for determination of dose calibrator linearity.

Linearity will be measured using the "Calicheck" device from Nuclear Medicine Consulting Firm. All instructions and directions given by the manufacturer will be followed. Enclosed you will find a description of the device taken from the product catalog.

Please note that we are proposing this as an alternative procedure. Measurement will be made with either the method described in our license currently or the proposed new method.



Dose Calibrator Linearity Test Kit

Easily checks linearity in minutes without sample decay or fractionating

- · Fast, accurate and reliable.
- · Eliminates costly waste of radionuclide.
- Meets NRC and Agreement State guidelines*.

The unique "Calicheck" Kit allows you to verify the linearity of your dose calibrator accurately and reliably—in minutes rather than days. No longer need you follow the decay of "To for three days or more to collect data for this test. Radiation exposure is reduced radically, and the radionuclide can still be used for imaging. Testing with "Calicheck" allows the calibrator, isotope and you to return to productive service in minutes. Since the kit works so fast, linearity tests can be made more frequently to spot trouble before it becomes serious.

"Calicheck" is designed to attenuate "Te by known values. It provides for seven successive measurements of a vial of "Te, using radiation-absorbing shields that simulate decay at approximately 0, 6, 12, 20, 30, 40 and 50 hours from the initial assay.

Operation is simple. The central tube, with a vial of "To inserted, is placed in the dose calibrator and counted, providing a "0" hour reading. Then, in sequence, each of the remaining color-coded tubes is positioned over the central tube and counted individually. The readings are then normalized with predetermined factors, and the degree of linearity can be seen virtually at a glance.

The "Calicheck" Kit includes seven color-coded, lead-wrapped plastic tubes, a supply of record-keeping sheets, and complete instructions. Maximum tube size is 11½" long x 1½%" diam. Will accept vials up to 30 cc (maximum 30-mm D.). Typical tube absorption factors for "TC: 1, 2, 3, 5, 10, 30, 120 and 350. Storage container 13½" high x 6" D. Net weight 10 lbs.

34-210 "Calicheck" Linearity Test Kit\$375.00

*NRC Regulatory Guide 10.8, Appendix D.